|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines显示文摘SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain(RBD)and N-terminal domain(NTD).Here we report the humoral immune response to circulating SARS-CoV-2 variants,such as 501Y.V2(B.1.351),of the plasma and neutralizing antibodies(NAbs)elicited by CoronaVac(inactivated vaccine),ZF2001(RBD-subunit vaccine)and natural infection.Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents,near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination,with E484K being the dominant cause.VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants,and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions.In contrast,the 242–244 deletion(242–244Δ)would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite,indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs.Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo-and authentic 501Y.V2 variants,mainly caused by E484K/N501Y and 242–244Δ,with the effects being additive.Importantly,RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents,since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations.Moreover,an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration.Together,these results suggest that the deployment of RBD-vaccines,through a third-dose boost,may be ideal for combating SARS-CoV-2 variants when necessary,especially for those carrying mutations that disrupt the NTD supersite. | Yunlong Cao Ayijiang Yisimayi Yali Bai Weijin Huang Xiaofeng Li Zhiying Zhang Tianjiao Yuan Ran An Jing Wang Tianhe Xiao Shuo Du Wenping Ma Liyang Song Yongzheng Li Xiang Li Weiliang Song Jiajing Wu Shuo Liu Xuemei Li Yonghong Zhang Bin Su Xianghua Guo Yangyang Wei Chuanping Gao Nana Zhang Yifei Zhang Yang Dou Xiaoyu Xu Rui Shi Bai Lu Ronghua Jin Yingmin Ma Chengfeng Qin Youchun Wang Yingmei Feng Junyu Xiao Xiaoliang Sunney Xie | 2021 | Cell Research2021，31，7： | 12 |
| 2 | Disease profile and plasma neutralizing activity of postvaccination Omicron BA.1 infection in Tianjin,China:a retrospective study显示文摘Dear Editor,SARS-CoV-2 Omicron variant BA.1 first emerged on the Chinese mainland on January 8,2022,in Tianjin and caused a large wave of infections.1 Four rounds of mass testing of its~14 million residents were launched on January 9,12,15,and 20,respectively.As of February 7,2022,a total of 430 individuals were tested positive for Omicron BA.1,with no new infections detected for the following 16 days.In the Chinese mainland,the most delivered vaccines are inactivated vaccines.As of January 8,2022,up to 93.2%of Tianjin’s residents had been vaccinated with at least one dose.2 We investigated the protection conferred by vaccination against Omicron BA.1 by examining the breakthrough infections among vaccinees as compared with unvaccinated cases.Our study population comprised all 430 cases during the outbreak of Omicron BA.1 in Tianjin. | Hong Zheng Yunlong Cao Xiaosu Chen Fengmei Wang Ye Hu Weiliang Song Yangyang Chai Qingqing Gu Yansong Shi Yingmei Feng Shuxun Liu Yan Xie Xiaoliang Sunney Xie Wentao Jiang Zhongyang Shen | 2022 | Cell Research2022，32，8： | 12 |
| 3 | Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine显示文摘Dear Editor,COVID-19 vaccination campaigns are being conducted in countries worldwide,and 47.4% of the world population has received at least one dose of a COVID-19 vaccine.1 Although vaccination has shaped COVID-19 epidemic curves,waning antibody levels and relatively short-duration protection provided by current COVID-19 vaccines have been observed,especially against SARS-CoV-2 variants of concern(VOCs)and among older individuals. | Yunlong Cao Xiaohua Hao Xi Wang Qianhui Wu Rui Song Dong Zhao Weiliang Song Yao Wang Ayijiang Yisimayi Wei Wang Juan Du Hongjie Yu Xiaoliang Sunney Xie Ronghua Jin | 2022 | Cell Research2022，32，1： | 8 |
| 4 | Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants显示文摘Dear Editor,The spread of the SARS-CoV-2 variants,especially the global variants of concern(VOCs),could seriously dampen our efforts to tackle the COVID-19 pandemic.The SARS-CoV-2 spike protein recognizes the host angiotensin-converting enzyme 2(ACE2)via its receptor-binding domain(RBD)to mediate viral entry into the cells.Several notorious mutations have been identified in the spike RBD of the VOCs.For example,B.1.1.7(Alpha),B.1.351(Beta),and P.1(Gamma)all contain the N501Y mutation,which increases the binding affinity for human ACE2 and confers higher infectivity in mice. | Shuo Du Pulan Liu Zhiying Zhang Tianhe Xiao Ayijiang Yasimayi Weijin Huang Youchun Wang Yunlong Cao Xiaoliang Sunney Xie Junyu Xiao | 2021 | Cell Research2021，31，10： | 3 |
| 5 | Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel:An Open-Label,Blank-Controlled Study—Hohhot City,Inner Mongolia Autonomous Region,China,2022显示文摘Summary What is already known about this topic?The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron subvariants in vitro studies.What is added by this report?This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019(COVID-19)infection in medical personnel for the first time.What are the implications for public health practice?This study provides an effective approach for the public to reduce their risk of COVID-19 infection.The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak. | Shujie Si Canrui Jin Jianping Li Yunlong Cao Biao Kan Feng Xue Xiaoliang Sunney Xie Liang Fang Gang Zeng Shuo Zhang Yaling Hu Xiaoping Dong | 2023 | China CDC weekly2023，5，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员